Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma
- Author
- GOY, Andre; YOUNES, Anas; BROGLIO, Kristine; SAMUELS, Barry; GILLES, Frederic; SARRIS, Andreas H; HART, Susan; TREHU, Elizabeth; SCHENKEIN, David; CABANILLAS, Fernando; RODRIGUEZ, Alma M; MCLAUGHLIN, Peter; PRO, Barbara; ROMAGUERA, Jorge E; HAGEMEISTER, Frederick; FAYAD, Luis; DANG, Nam H; SAMANIEGO, Felipe; WANG, Michael
Departments of Lymphoma and Myeloma, Molecular Pathology, Biostatistics, and Imaging, The University of Texas M.D. Anderson Cancer Center, Houston TX, United States
Hematology Oncology Department, Hygeia Hospital, Athens, Greece
Millennium Pharmaceuticals, Inc, Cambridge, MA, United States - Source
Journal of clinical oncology. 2005, Vol 23, Num 4, pp 667-675, 9 p ; ref : 30 ref
- ISSN
- 0732-183X
- Scientific domain
- Medical oncology
- Publisher
- Lippincott Williams & Wilkins, Baltimore, MD
- Publication country
- United States
- Document type
- Article
- Language
- English
- Keyword (fr)
- Anticancéreux Bortézomib Cancérologie Essai clinique phase II Inhibiteur Lymphocyte B Lymphome non hodgkinien Multicatalytic endopeptidase complex Récidive Résistance traitement Traitement Enzyme Hydrolases Hémopathie maligne Lymphoprolifératif syndrome Peptidases
- Keyword (en)
- Antineoplastic agent Bortezomib Cancerology Phase II trial Inhibitor B-Lymphocyte Non Hodgkin lymphoma Multicatalytic endopeptidase complex Relapse Treatment resistance Treatment Enzyme Hydrolases Malignant hemopathy Lymphoproliferative syndrome Peptidases
- Keyword (es)
- Anticanceroso Bortezomib Cancerología Ensayo clínico fase II Inhibidor Linfocito B Linfoma no Hodgkin Multicatalytic endopeptidase complex Recaida Resistencia tratamiento Tratamiento Enzima Hydrolases Hemopatía maligna Linfoproliferativo síndrome Peptidases
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B19 Hematologic and hematopoietic diseases / 002B19B Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
- Discipline
- Blood diseases Tumours
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 16478125
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1200/JCO.2005.03.108 
https://dx.doi.org/10.1200/JCO.2005.03.108
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:23:\"10.1200\/JCO.2005.03.108\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:105:\"Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Journal of clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2005\";s:9:\"\u0000*\u0000volume\";s:2:\"23\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:3:\"667\";s:8:\"\u0000*\u0000epage\";s:3:\"675\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0732-183X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:3:\"GOY\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Andre\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:18:{i:0;s:12:\"YOUNES, Anas\";i:1;s:17:\"BROGLIO, Kristine\";i:2;s:14:\"SAMUELS, Barry\";i:3;s:16:\"GILLES, Frederic\";i:4;s:17:\"SARRIS, Andreas H\";i:5;s:11:\"HART, Susan\";i:6;s:16:\"TREHU, Elizabeth\";i:7;s:16:\"SCHENKEIN, David\";i:8;s:20:\"CABANILLAS, Fernando\";i:9;s:17:\"RODRIGUEZ, Alma M\";i:10;s:17:\"MCLAUGHLIN, Peter\";i:11;s:12:\"PRO, Barbara\";i:12;s:18:\"ROMAGUERA, Jorge E\";i:13;s:22:\"HAGEMEISTER, Frederick\";i:14;s:11:\"FAYAD, Luis\";i:15;s:11:\"DANG, Nam H\";i:16;s:17:\"SAMANIEGO, Felipe\";i:17;s:13:\"WANG, Michael\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:105:\"Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma\";s:8:\"\u0000*\u0000place\";s:13:\"Baltimore, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:23:\"10.1200\/JCO.2005.03.108\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:105:\"Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Journal of clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2005\";s:9:\"\u0000*\u0000volume\";s:2:\"23\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:3:\"667\";s:8:\"\u0000*\u0000epage\";s:3:\"675\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0732-183X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:3:\"GOY\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Andre\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:18:{i:0;s:12:\"YOUNES, Anas\";i:1;s:17:\"BROGLIO, Kristine\";i:2;s:14:\"SAMUELS, Barry\";i:3;s:16:\"GILLES, Frederic\";i:4;s:17:\"SARRIS, Andreas H\";i:5;s:11:\"HART, Susan\";i:6;s:16:\"TREHU, Elizabeth\";i:7;s:16:\"SCHENKEIN, David\";i:8;s:20:\"CABANILLAS, Fernando\";i:9;s:17:\"RODRIGUEZ, Alma M\";i:10;s:17:\"MCLAUGHLIN, Peter\";i:11;s:12:\"PRO, Barbara\";i:12;s:18:\"ROMAGUERA, Jorge E\";i:13;s:22:\"HAGEMEISTER, Frederick\";i:14;s:11:\"FAYAD, Luis\";i:15;s:11:\"DANG, Nam H\";i:16;s:17:\"SAMANIEGO, Felipe\";i:17;s:13:\"WANG, Michael\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:105:\"Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma\";s:8:\"\u0000*\u0000place\";s:13:\"Baltimore, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:23:\"10.1200\/JCO.2005.03.108\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:23:\"10.1200\/JCO.2005.03.108\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:105:\"Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Journal of clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2005\";s:9:\"\u0000*\u0000volume\";s:2:\"23\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:3:\"667\";s:8:\"\u0000*\u0000epage\";s:3:\"675\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0732-183X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:3:\"GOY\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Andre\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:18:{i:0;s:12:\"YOUNES, Anas\";i:1;s:17:\"BROGLIO, Kristine\";i:2;s:14:\"SAMUELS, Barry\";i:3;s:16:\"GILLES, Frederic\";i:4;s:17:\"SARRIS, Andreas H\";i:5;s:11:\"HART, Susan\";i:6;s:16:\"TREHU, Elizabeth\";i:7;s:16:\"SCHENKEIN, David\";i:8;s:20:\"CABANILLAS, Fernando\";i:9;s:17:\"RODRIGUEZ, Alma M\";i:10;s:17:\"MCLAUGHLIN, Peter\";i:11;s:12:\"PRO, Barbara\";i:12;s:18:\"ROMAGUERA, Jorge E\";i:13;s:22:\"HAGEMEISTER, Frederick\";i:14;s:11:\"FAYAD, Luis\";i:15;s:11:\"DANG, Nam H\";i:16;s:17:\"SAMANIEGO, Felipe\";i:17;s:13:\"WANG, Michael\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:105:\"Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma\";s:8:\"\u0000*\u0000place\";s:13:\"Baltimore, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:23:\"10.1200\/JCO.2005.03.108\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:105:\"Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Journal of clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2005\";s:9:\"\u0000*\u0000volume\";s:2:\"23\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:3:\"667\";s:8:\"\u0000*\u0000epage\";s:3:\"675\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0732-183X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:3:\"GOY\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Andre\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:18:{i:0;s:12:\"YOUNES, Anas\";i:1;s:17:\"BROGLIO, Kristine\";i:2;s:14:\"SAMUELS, Barry\";i:3;s:16:\"GILLES, Frederic\";i:4;s:17:\"SARRIS, Andreas H\";i:5;s:11:\"HART, Susan\";i:6;s:16:\"TREHU, Elizabeth\";i:7;s:16:\"SCHENKEIN, David\";i:8;s:20:\"CABANILLAS, Fernando\";i:9;s:17:\"RODRIGUEZ, Alma M\";i:10;s:17:\"MCLAUGHLIN, Peter\";i:11;s:12:\"PRO, Barbara\";i:12;s:18:\"ROMAGUERA, Jorge E\";i:13;s:22:\"HAGEMEISTER, Frederick\";i:14;s:11:\"FAYAD, Luis\";i:15;s:11:\"DANG, Nam H\";i:16;s:17:\"SAMANIEGO, Felipe\";i:17;s:13:\"WANG, Michael\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:105:\"Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma\";s:8:\"\u0000*\u0000place\";s:13:\"Baltimore, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
